IFNA1 and cyclic hematopoiesis: Based on these and some other landmark studies, current guidelines suggest considering an HBV nucleo(s)tide analogue in addition to peg-IFN-α only for the few HDV-CH patients with ongoing HBV DNA replication [92,94].